Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Steroidal mineralocorticoid receptor antagonists reduce morbidity and mortality among patients with heart failure and reduced ejection fraction, but their efficacy in those with heart failure and mildly reduced or preserved ejection fraction has not been established. Data regarding the efficacy and safety of the nonsteroidal mineralocorticoid receptor antagonist finerenone in patients with heart failure and mildly reduced or preserved ejection fraction are needed. METHODS: In this international, double-blind trial, we randomly assigned patients with heart failure and a left ventricular ejection fraction of 40% or greater, in a 1:1 ratio, to receive finerenone (at a maximum dose of 20 mg or 40 mg once daily) or matching placebo, in addition to usual therapy. The primary outcome was a composite of total worsening heart failure events (with an event defined as a first or recurrent unplanned hospitalization or urgent visit for heart failure) and death from cardiovascular causes. The components of the primary outcome and safety were also assessed. RESULTS: Over a median follow-up of 32 months, 1083 primary-outcome events occurred in 624 of 3003 patients in the finerenone group, and 1283 primary-outcome events occurred in 719 of 2998 patients in the placebo group (rate ratio, 0.84; 95% confidence interval [CI], 0.74 to 0.95; P = 0.007). The total number of worsening heart failure events was 842 in the finerenone group and 1024 in the placebo group (rate ratio, 0.82; 95% CI, 0.71 to 0.94; P = 0.006). The percentage of patients who died from cardiovascular causes was 8.1% and 8.7%, respectively (hazard ratio, 0.93; 95% CI, 0.78 to 1.11). Finerenone was associated with an increased risk of hyperkalemia and a reduced risk of hypokalemia. CONCLUSIONS: In patients with heart failure and mildly reduced or preserved ejection fraction, finerenone resulted in a significantly lower rate of a composite of total worsening heart failure events and death from cardiovascular causes than placebo. (Funded by Bayer; FINEARTS-HF ClinicalTrials.gov number, NCT04435626.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Over the past decade, the use of medications that have been demonstrated to be effective in patients with HF with reduced ejection fraction (angiotensin receptor neprilysin inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter 2 [SGLT2] inhibitors) has been evaluated in large-scale trials in patients with HF and mildly reduced ejection fraction and patients with HFpE”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“This level was significantly lower than that in the STEP-HFpEF program (median, ≈470 pg/mL)36 and substantially lower than in other large-scale outcome trials in HFpEF (median 900–1400 pg/mL).3–6”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Of the enrolled participants, 41% had type 2 diabetes.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [303]
The cited source says what the claim attributes to it.
In the citing paper
“The selective nonsteroidal MRA finerenone was examined in the Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40% (FINEARTS-HF) trial of people with symptomatic HFpEF (ejection fraction ≥40%) and was found to reduce the risk of”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [303]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Self-citationPitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Self-citationEmpagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Self-citationEplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111
Self-citationEffect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Self-citationDapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Claggett, B., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206286 · Cited by 2,884
Self-citationSpironolactone for heart failure with preserved ejection fraction
Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313731 · Cited by 2,809
Self-citationAngiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908655 · Cited by 2,430
Self-citationSotagliflozin in patients with diabetes and recent worsening heart failure
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868
Self-citationCardiovascular events with finerenone in kidney disease and type 2 diabetes
Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110956 · Cited by 1,814
Self-citation
Cited by
Items 301–400 of 892
Laborante, R., Paglianiti, D. A., Elia, S., Patti, G., Girerd, N., Savarese, G., & D'Amario, D. (2026) · ESC Heart Failure · doi:10.1093/eschf/xvag018 · Cited by 3
Kidney Protection Options in 2025: Are Renin-Angiotensin System Inhibitors Still Needed?
Weir, M. R. (2026) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2026.151688 · Cited by 4
Datta, S., Majumder, S., Gulsin, G. S., Banerjee, A., Primus, C., Mohammed, S., Ricci, F., Aung, N., Sen, G., Gallagher, A. M., et al. (2026) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcag029 · Cited by 4
“43 The ongoing FINALITY-HF trial (NCT06033950) is investigating their efficacy in HFrEF patients who are intolerant to currently recommended steroidal MRAs.”
Soltani, F., Black, N., Bradley, J., Priestner, L., Ko, N. K., Glasse, H., Milner, I., Kreppel, S., Schmitt, M., Nucifora, G., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag056 · Cited by 4
Self-citationGötzinger, F., Stolte, T., Reichl, J. J., von Peter, A., Kunz, M., Wild, M. G., Wagener, M., Kaiser, C., Mueller, C. E., Westermann, D., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag075 · Cited by 3
Coca, A., Sanchez, R., SALAZAR, D. I. M. D., Peñaherrera, E., Alcocer, L., Barbosa, E., Grassi, G. M., López-Jaramillo, P. A., Lurbe, E., Parra-Carrillo, J. Z., et al. (2026) · Journal of Hypertension · doi:10.1097/hjh.0000000000004290 · Cited by 4
Zhu, L., Gu, T., Zhang, Y.-K., Hu, S., Shao, X., Zhang, H., Zhao, J., Liu, X., Liu, T., & Chen, K. Y. (2026) · The American Journal of Medicine · doi:10.1016/j.amjmed.2026.03.049 · Cited by 3
Geraci, G., Sinatra, N., Paternò, V., Calabrese, V., Cassataro, G., Cuttone, G., Geraci, C., Esposito, R., Mancusi, C., Pucci, G., et al. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-026-07890-7 · Cited by 3
“More recently, the FINEARTS-HF trial extended these findings to patients with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF), irrespective of diabetes status, thereby broadening the therapeutic scope of finerenone across the cardiorenal continuum [16 ].”
Renin, Aldosterone, and Treatment Response to Dapagliflozin, Spironolactone, and Their Combination
Ferreira, J. P., Marques, P. S., Neves, J. S., Leite, A. R., Teixeira, C., Saraiva, F. S., Sharma, A., Zannad, F. M., Pimenta, J., Fontes-Carvalho, R., et al. (2026) · JACC Heart Failure · doi:10.1016/j.jchf.2026.103111 · Cited by 3
Self-citationJelwan, Y. A., Cao, T., Yao, Z., Burka, S., Erhabor, J., Berning, P., Dzaye, O. D. A., & Blaha, M. J. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.046837 · Cited by 4
“The Kidney Disease: Improving Global Outcomes guidelines provide a class 2A recommendation for finerenone for CKD and T2D indication, 14 but US-based cardiology guidelines have only recently begun to reflect its potential role.”
Rao, V. S., Ivey-Miranda, J. B., Cox, Z. L., Wilson, F. P., Petrie, M. C., Sarnak, M. J., Wilcox, C. S., Pitt, B., McCallum, W. I., & Testani, J. M. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag440 · Cited by 3
Self-citationThe therapeutic approach to cardiovascular–kidney–metabolic syndrome
Rangaswami, J., Lo, K. B., & Ndumele, C. E. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-026-01109-6 · Cited by 4
“The FINEARTS-HF trial in patients with HF with mildly reduced or preserved ejection fraction (LVEF ≥40%), showed that finerenone treatment resulted in reduction in the composite of total worsening HF events and death from cardiovascular causes (HR 0.84, 95% CI 0.74– 0.95) 76 .”
InfluentialDeprescribing strategies in older patients with heart failure
Tersalvi, G., Beltrani, V., Peronti, M., Furlan, L., Foy, A., & Biasco, L. (2024) · Internal and Emergency Medicine · doi:10.1007/s11739-024-03791-5 · Cited by 6
Halaseh, R., Sauer, A. J., Vardeny, O., Canonico, M. E., Harrington, J., Svetlichnaya, J., & Ambrosy, A. P. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10462-2 · Cited by 4
Self-citationDiuretic strategies in acute decompensated heart failure
Lo, K. B., & Nohria, A. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10473-z · Cited by 3
The year in cardiovascular medicine 2024: the top 10 papers in heart failure
Bauersachs, J. K., Zieroth, S. R., & de Boer, R. A. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf017 · Cited by 3
Self-citationBestetti, R. B., Otaviano, A. P., Cardinalli-Neto, A., Machado, M. D. N., & Nakazone, M. A. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133088 · Cited by 3
Salinas, G. L. A., León, A. M., Cano, D. A., Esteban‐Fernández, A., Flórez, J. M. V., Díaz, S. D. P., Magaña, J. G., Delgado, G. D. L., Manzanares, R. G., Caravaca-Pérez, P., et al. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15260 · Cited by 4
Madsen, J. M., Engstrøm, T., Kelbæk, H., Beske, R. P., Islam, U., Høfsten, D. E., Holmvang, L., Pedersen, F., Terkelsen, C. J., Christiansen, E. H., et al. (2025) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.125.015369 · Cited by 3
Agarwal, R., Nangaku, M., Chen, L., Wang, A. Y.-M., Yanagita, M., Bavanandan, S., Satirapoj, B., Prasad, N., Lim, S. K., Sriwijitkamol, A., et al. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000909 · Cited by 6
Pharmacological management of heart failure: a patient-centred approach
Fibbi, G., Sato, R., Vatic, M., Genreith, F. P., & von Haehling, S. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2418414 · Cited by 6
“For what concerns patients with HFmrEF and HFpEF, the FINEARTS-HF trial recently demonstrated that finerenone significantly reduced the composite outcome of total worsening HF events and death from CV causes in patients with HFmrEF or HFpEF [46].”
Lee, C.-C., Kuan, D. T.-W., Chang, K.-C., Chen, Z., Cheng, J., Lin, T., Lin, L., & Wu, C. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1507326 · Cited by 3
Opportunities and challenges in preventing heart failure: when is risk modifiable?
Lindberg, F., & Savarese, G. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf042 · Cited by 3
Huart, J., & Jouret, F. (2025) · Kidney and Blood Pressure Research · doi:10.1159/000545286 · Cited by 3
“More recently, the FINEARTS-HF trial assessed the effects of fi nerenone in patients with symptomatic HF, 40.5% of whom had type 2 diabetes mellitus (T2DM) [13].”
InfluentialAntihypertensive drug treatment: are we ready for the future?
Danser, A. H. J., & Deinum, J. (2025) · Journal of Hypertension · doi:10.1097/hjh.0000000000004019 · Cited by 3
How to Enhance Cardiorenal Benefits in Patients With Chronic Heart Failure?
Izumida, T., & Kinugawa, K. (2025) · International Journal of Heart Failure · doi:10.36628/ijhf.2025.0004 · Cited by 3
“98)”
Sindone, A. P., Abhayaratna, W. P., Chan, A., Leung, M., Hopper, I., Amerena, J. V., Pasquale, C. G. D., Burdeniuk, C., Coats, A. J. S., & Atherton, J. J. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.08.010 · Cited by 6
Self-citationNatriuretic Peptides for the Diagnosis of Heart Failure With Preserved Ejection Fraction
Omland, T., & Mills, N. L. (2025) · Circulation · doi:10.1161/circulationaha.125.073788 · Cited by 4
Madaudo, C., Bromage, D. I., & Cannata, A. N. (2025) · Future Cardiology · doi:10.1080/14796678.2025.2490403 · Cited by 4
Meyer, P., Rocca, A., Banús, J., Ogier, A. C. C., Georgantas, C., Calarnou, P., Fatima, A., Vallée, J., Deux, J., Thomas, A., et al. (2025) · medRxiv · doi:10.1101/2025.04.10.25325567 · Cited by 3
Assessing Medical Therapy Optimization in Cardiovascular-Kidney-Metabolic Clinical Trials
Bhatt, A. S., Oliveira-Gomes, D. D., Fiuzat, M., Vaduganathan, M., HAMO, C. E., Stockbridge, N., Butler, J., Psotka, M. A., Abraham, W. T., McGuire, D. K., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102727 · Cited by 3
Self-citationIzraiq, M., Jammal, M., Toubasi, A. A., Mari, S., AlNajafi, S., Al-Qadasi, A., Maharmeh, K. A., Almansour, M., Saleh, S., Ahmed, Y. B., et al. (2024) · PeerJ · doi:10.7717/peerj.18464 · Cited by 2
Have SGLT-2 inhibitors DELIVERed an EMPhatic win in heart failure and chronic kidney disease?
Singh, A. K., Singh, A., & Singh, R. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2464905 · Cited by 5
Cardiovascular-Kidney-Metabolic Health
Solomon, M., Claudel, S. E., & Verma, A. (2025) · Cardiology Clinics · doi:10.1016/j.ccl.2025.03.001 · Cited by 4
Preserving renal function: gliflozins, GLP1 agonists, and antialdosterones
Cice, G. (2025) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suaf019 · Cited by 3
Focus on finerenone: the FINEARTS-HF study
Tolone, S., Tinti, M. D., Pulignano, G., Natale, E., & Gabrielli, D. (2025) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suaf035 · Cited by 2
Lisi, D. L., Gaddis, K., & Abdou, M. H. (2025) · Medical Clinics of North America · doi:10.1016/j.mcna.2025.04.003 · Cited by 2
Yaakoubi, H., Boukadida, L., Toumia, M., Caillard, A., Soltane, H. B., Jaballah, R., Trabelsi, I., Dhaoui, R., Zorgati, A., Boubaker, H., et al. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15373 · Cited by 2
Mohammed, A. S., Ahmed, H., Singh, S., Munguti, C., Subramanian, L., Srikanth, S., Kodali, L. S. M., Takagi, M. A., Yasmeen, U., Imtiaz, H., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14155495 · Cited by 2
“Finerenone, a mineralocorticoid receptor antagonist, is FDA-approved for patients with chronic kidney disease and type 2 diabetes and has demonstrated benefit in those with preserved ejection fraction [29].”
Characteristic analysis of adverse reactions of finerenone: an in-depth analysis from WHO-VigiAccess
Fan, H., Huang, Z., Yang, Y., Li, J., & Zhou, B. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1545148 · Cited by 3
Diagnose und Therapie der Herzinsuffizienz mit erhaltener Ejektionsfraktion
Soltani, S., & Bauersachs, J. K. (2025) · Herz · doi:10.1007/s00059-025-05327-9 · Cited by 2
Self-citationHeng, Z., Hong, M., Zhang, Z., Ye, X., Zhou, J., Wu, W., Rong, J., & Xu, Y. (2025) · Advanced Science · doi:10.1002/advs.202507554 · Cited by 3
Lu, H. Y., Claggett, B. L., Vaduganathan, M., Desai, A. S., Jhund, P. S., Voors, A. A., Senni, M., Zannad, F. M., Pitt, B., Shah, S. J., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102590 · Cited by 8
Self-citationPeng, S. A., Li, P., Yu, Z., Du, B., & Yang, P. C. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1575307 · Cited by 2
Dynamic Tricuspid Regurgitation in Heart Failure with Preserved Ejection Fraction
Harada, T., Reddy, Y. N. V., Sorimachi, H., Obokata, M., Naser, J. A., Tada, A., Doi, S., Ibe, T., Eleid, M. F., Pislaru, S. V., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70050 · Cited by 6
Reddy, Y. N. V., DeFranco, S., Lerman, A., Demmer, R. T., Chamberlain, A. M., Somers, V. K., & Borlaug, B. A. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2025.07.009 · Cited by 4
Shimada, H., Mizuno, K., & Kawakami, K. (2025) · Heart and Vessels · doi:10.1007/s00380-025-02609-4 · Cited by 2
New and Emerging Nonimmunosuppressive Drug Therapies for Primary Adult Glomerular Diseases
Mushailov, V., & Radhakrishnan, J. (2025) · Kidney Medicine · doi:10.1016/j.xkme.2025.101133 · Cited by 2
Desai, N. R., Ahmad, T., & Wilson, F. P. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10564-5 · Cited by 4
de la Rambelje, M. A., Voors, A. A., Greasley, P. J., Berger, M., & Heerspink, H. J. L. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70193 · Cited by 3
Self-citationThe Problem with Hospitalization Endpoints in Heart Failure Trials
Straw, S., Martens, P., Mewton, N., Witte, K. K., & Müllens, W. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70070 · Cited by 2
Massad, F., Badwan, O. Z., Rosenzveig, A., Zghyer, F., Shahrori, Z., Motairek, I. K., Hatab, T., Alkhatib, R., & Kapadia, S. R. (2025) · Structural Heart · doi:10.1016/j.shj.2025.100751 · Cited by 2
Rai, B., Dar, S. F., Alowami, M., Sajjad, R., Agarwal, T., Khan, M. H., Ali, S. R. M., Kamran, G., Thomas, R. P., Mudiyanselage, N. S. B. A., et al. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001068 · Cited by 2
Finerenone in Patients with Severe Heart Failure: The FINEARTS-HF Trial
Inciardi, R. M., Lu, H. Y., Claggett, B. L., Desai, A. S., Jhund, P. S., Henderson, A. D., Lam, C. S. P., Merkely, B. P., Miao, M. Z., Senni, M., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70083 · Cited by 2
Self-citationUpdate on clinical heart failure trials
Hoevelmann, J., Tokcan, M., Kulenthiran, S., Abdin, A., Viljoen, C. A., & Böhm, M. (2025) · Clinical Research in Cardiology · doi:10.1007/s00392-025-02784-4 · Cited by 2
Manon, M.-F., Pieronne-Deperrois, M., Bonnard, B., Coralie, F., Kong, L., Amhrae, N. D., Nicol, L., Morchid, S., Renet, S., Dumesnil, A., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02935-x · Cited by 2
“…Receptor antagonist Tolerability Study-HF) in patients with HFpEF or with mildly reduced EF (HFm-rEF), treatment with finerenone in addition to usual therapy resulted in a lower rate of the primary composite endpoint of total worsening of HF events and cardiovascular mortality [47].”
Alawoad, Z., Jensen, J., Schou, M., Ahmed, N., Attia, A. E., Rao, S., Rahimi, K., & Wamil, M. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10577-0 · Cited by 4
Self-citationAdvancing Cardiorenal Interaction: From Pathophysiological Paradigms to Novel Therapeutic Strategies
Wei, L., He, P., Gao, J., Huang, L., Zhao, L., Zhang, R., Ning, X., & Sun, S. (2025) · Kidney Diseases · doi:10.1159/000548367 · Cited by 2
“In the existing phase 4 randomized controlled trials (FIDELIO-DKD [92], FIGARO-DKD [93], FIDELITY [94], and FI-NEARTS-HF [95]), finerenone exhibited a remarkable reduction in urine albumin-creatinine ratio reduction of 31–32% compared with placebo after 4 months (Table 4), satisfying the goal of a…”
Shah, S. J. (2025) · Structural Heart · doi:10.1016/j.shj.2025.100778 · Cited by 2
“For example, in the FINEARTS-HF trial, the rate of HF hospitalization or cardiovascular death was 14.9 per 100 patient-years in those randomized to finerenone, 5 whereas the risk in those without HF over the age of 65 years is ~1.2-1.5 per 100 patient-years.”
InfluentialSelf-citationPANNEFLEK, J., Barbarawi, M., KAKARLAPUDI, Y., Barbarawi, Z., Lauzea, B., & Meraz-Torres, M. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07821-y · Cited by 3
Risk Stratification Tools in Acute Heart Failure and Their Roles in Personalized Follow-Up
Rizzello, V., Carigi, S., Maria, R. D., Tinti, M. D., Limonta, R., Orso, F., Bianco, M., Gennaro, L. D., Matassini, M. V., Manca, P., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14248937 · Cited by 3
“Once reversible or specific causes are excluded, treatment with SGLT2 inhibitors and, based on the recent results of the FINEARTS-HF trial, finerenone should be initiated [61].”
The mineralocorticoid receptor: a new chapter for therapeutic regulation of diabetic cardiomyopathy
Kanki, M., & Young, M. J. (2026) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2026.01.004 · Cited by 3
Consensus document on the diagnosis and treatment of acute kidney injury
Ramos-Terrades, N., Benítez, P. R., Gallardo, J. M. U., Valdenebro, M., Salgueira, M., Andújar, A. M., Martins, J., Ramos-Galí, A., Moreno, J. A., Cuerda, C., et al. (2026) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2026.501360 · Cited by 5
“Furthermore, hypochlor-emia is associated with a worse diuretic response in acute HF.”
InfluentialErzeel, J., Es, M. V., Müllens, W., & Martens, P. (2026) · Current Heart Failure Reports · doi:10.1007/s11897-026-00740-5 · Cited by 2
“However, CV death alone was not significantly reduced (8.1% for finere - none versus 8.7% for placebo) [55 ].”
InfluentialTen Hot Topics in Cardiovascular Risk Management for Chronic Kidney Disease
Marqués, M., Ortíz, A., Romero-González, G. A., Díez, J., Santamaría, R., Puente-García, A., Alcázar, R., de Sequera, P., Górriz, J. L., & Quiroga, B. (2026) · Cardiorenal Medicine · doi:10.1159/000550943 · Cited by 2
Spagnolin, M., Fazzini, L., Giaccherini, C., D’Elia, E., Chiesa, E., Zucchi, A., Gavazzi, A., Senni, M., & Gori, M. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag037 · Cited by 2
Self-citationArshad, M. S., Saad, M., Lurz, P. C., Rommel, K., Khan, M., Bangalore, S., Aronow, H. D., Swaminathan, R. V., Gutiérrez, J. A., & Fudim, M. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10600-y · Cited by 2
Treatment of Primary Aldosteronism
Salle, S. P., Hundemer, G. L., Nehs, M. A., Barletta, J. A., & Vaidya, A. (2026) · Hypertension · doi:10.1161/hypertensionaha.126.26238 · Cited by 4
Rocha-Oliveira, E., Lagrange, J., Jahangiri, M., Guerci, P., Baudry, G., Mercier, N., Monzo, L., Leroy, C., Lamiral, Z., Leite-Moreira, A. F., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.044788 · Cited by 2
“3,4 Among these factors, inflammation has long been recognized as a central mechanistic link between cardiovascular comorbidities and vascular alterations in HFpEF.”
Self-citationSebastian, S. A., Ayyalu, T., Bimal, T., Patel, B., Kittleson, M. M., Carbone, S., & Yehya, A. (2026) · Disease-a-Month · doi:10.1016/j.disamonth.2026.102099 · Cited by 2
Lu, H. Y., Kosztin, A., Claggett, B. L., Foà, A., Pabón, M. A., Desai, A. S., Jhund, P. S., Henderson, A. D., Merkely, B. P., Lam, C. S. P., et al. (2026) · JAMA Cardiology · doi:10.1001/jamacardio.2026.0682 · Cited by 3
Self-citationHypertensive Heart Disease and HFpEF: What We Have Learned in the Last Decade
Ono, R., & Falcão, L. M. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.04.006 · Cited by 3
Wu, L. H., Pakkiri, L. S., Tromp, J., Lim, P. L., Liu, X. D., Chan, S. P., Yang, J., Samant, R., Dong, J., Goh, E. C. H., et al. (2026) · Cardiovascular Research · doi:10.1093/cvr/cvag090 · Cited by 2
“2,3 Despite therapeutic advances, both HF subtypes, particularly HFpEF, still carry substantial residual risks that must be better quantified and managed, underscoring the urgent need to delineate their distinct pathological drivers.”
Self-citationMallardo, M., Filardi, P. P., Micheletto, C., Montano, N., Spampinato, A., Volterrani, M., Zito, G., Agosti, S., Avogadri, E., Basile, C., et al. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.106881 · Cited by 2
Self-citationHeart Failure in Type 1 vs. Type 2 Diabetes Mellitus: Shared Pathways, Distinct Challenges
Hussain, M. S., Iyer, S., Liew, Y. J., Win, M. L., McCrimmon, R. J., Lang, C. C., & Mordi, I. R. (2026) · Journal of Diabetes Research · doi:10.1155/jdr/7460084 · Cited by 2
Zuin, M., Bilato, C., Temporelli, P. L., Oliva, F. G., Savarese, G., Metra, M., Filippatos, G. S., Corsini, A., Goldhaber, S. Z., & Piazza, G. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag150 · Cited by 2
Self-citationXu, T., Liu, X., Zhao, J., Han, X., Gu, T. S., Chen, K.-Y., Korantzopoulos, P. G., Lip, G. Y. H., & Liu, T. (2026) · European Heart Journal Open · doi:10.1093/ehjopen/oeag077 · Cited by 2
“In this study, intention-to-treatment analysis of real-world data from new users validated the effectiveness of finerenone in the non–clinical trial environment and supplemented the external validity of existed randomized controlled trials 7,8 among AF patients prescribed finerenone.”
Rationale and Design of the Türkiye Heart Failure (TURK‐HF) Registry
Kocabaş, U., Murat, S., Kıvrak, T., Murat, B., Altın, C., Yıldız, C., Polatkan, Ş. G., Oskay, S. A., Ulutaş, Z., İnan, D., et al. (2026) · Clinical Cardiology · doi:10.1002/clc.70353 · Cited by 2
“The results of phase 3 clinical trials with SGLT‐2 inhibitors and finerenone have demonstrated favorable outcomes in patients with HFmrEF and/or HFpEF [8–10].”
Spall, H. G. C. V., & Vardeny, O. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10636-0 · Cited by 3
Self-citationZakeri, R., & Nabeebaccus, A. (2026) · Clinical Medicine · doi:10.1016/j.clinme.2026.100608 · Cited by 4
Guidelines for the management of hereditary ATTR amyloidosis 2026
Sekijima, Y., Ueda, M., Berk, J. L., Obici, L. P., Witteles, R. M., Planté‐Bordeneuve, V., Weiler, M., Fontana, M., Waddington‐Cruz, M., Coelho, T., et al. (2026) · Amyloid · doi:10.1080/13506129.2026.2695368 · Cited by 5
“We recommend treatment with mineralocorticoid receptor antagonists [65] and sodium-glucose transporter 2 (SGLT2) inhibitors [66] for patients with cardiac amyloidosis who have clinically manifest heart failure and no significant autonomic dysfunction or orthostatic hypotension, based on their…”
Ostrominski, J. W., Claggett, B. L., Kulac, I. J., Desai, A. S., Jhund, P. S., Henderson, A. D., Lam, C. S. P., Senni, M., Shah, S. J., Voors, A. A., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag209 · Cited by 2
“14 Benefits of finerenone on cardiovascular and kidney events were also largely inde - pendent of BP changes in the FIDELIO-DKD (Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease) trial.”
InfluentialSelf-citationDamman, K., ter Maaten, J. M., Mayne, K. J., Bolignano, D., Brown, E. M., da Costa, B. R., Dagre, A. G., Gansevoort, R. T., Gavina, C., Goette, A., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag098 · Cited by 34
Chlorthalidone as Secondary Treatment in HFpEF?
Gelfman, D. M. (2024) · The American Journal of Medicine · doi:10.1016/j.amjmed.2024.09.027 · Cited by 2
Volpe, M., & Galiuto, L. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae679 · Cited by 2
Dawadi, S., Shrestha, D. B., Oli, P. R., Shtembari, J., Kansakar, S., Paudel, S., & Pant, K. (2024) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001661 · Cited by 2
“38,39 Evaluation and quanti fi cation of outcomes such as the left ventricular mass index, ejection fraction, and blood pressure could have led to a better understanding of the effect of MRA on the overall cardiovascular dynamics of the ESRD population.”
Monzo, L., Musella, F., Girerd, N., & Rossignol, P. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10490-6 · Cited by 2
Péč, M. J., Jurica, J., Bolek, T., Škorňová, I., Péčová, M., Cingel, M., Horná, S., Stančiaková, L., Staško, J., Tóth, Š., et al. (2025) · Metabolites · doi:10.3390/metabo15020091 · Cited by 2
“Finally, several novel drugs, namely finerenone, semaglutide, and tirzepatide, have been reported as effective for HFpEF or T2D and obesity-related HFpEF [35–38].”
Hypertension in chronic kidney disease and future heart failure
Burnier, M. (2025) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001206 · Cited by 2
Insights into Clinical Practice: A National Survey on Fluid Intake Management in Heart Failure
Höög, L., Strömberg, A., Waldréus, N., & Nymark, C. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15273 · Cited by 2
Kobayashi, M., Yamashina, A., Satomi, K., Watanabe, M., Takagi, R., Tezuka, A., Ito, S., Asakura, M., & Kitakaze, M. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02659-y · Cited by 3
“However, in this trial, finerenone was treated at relative low dose (≤ 20 mg/day), and when finerenone was used up to 40 mg/day in a population of HF and preserved ejection fraction, hyperkalemia risk was similar to what was reported in other steroidal MRAs [41, 42].”
Cardiology: What You May Have Missed in 2024
Khattak, S., Ansari, A., Alfaraidhy, M., Rajah, F. T., LaCombe, M. A., & Kussmaul, W. G. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-00991 · Cited by 2
Kim, H. (2025) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2025.5.e4 · Cited by 2
6. Cardio-renal protection in type 2 diabetes
Colagiuri, S., & Ceriello, A. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112150 · Cited by 6
Yoon, M., Park, J. J., Youn, J., Lee, S. E., Lee, H., Choi, J., Kim, K. H., Yang, D. H., Cho, M., Kang, S., et al. (2025) · International Journal of Heart Failure · doi:10.36628/ijhf.2025.0007 · Cited by 2
Self-citationSedrak, P., Verma, R., Verma, M., & Connelly, K. A. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.03.037 · Cited by 6
Heart Failure with Preserved Ejection Fraction
Mathew, D., Elghoul, Y., Bhattacharya, S., & Smith, D. T. (2025) · Medical Clinics of North America · doi:10.1016/j.mcna.2025.04.006 · Cited by 2
Optimizing Nephron Performance: The Old, the New, and the New–Old Diuretic Therapies
Fuchs, F. D., Procianoy, G. S., Bottino, L. G., Fuchs, S. C. P. C., & Whelton, P. K. (2025) · Biomedicines · doi:10.3390/biomedicines13061413 · Cited by 3
“A recent randomized controlled trial showed that finerenone reduced the rate of worsening heart failure events in patients with a mildly reduced or preserved ejection fraction (HR 0.82 95% CI 0.71–0.94) [49].”
InfluentialZubair, M., & Khan, S. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07743-9 · Cited by 2
“A recent study published in NEJM shows that finerenone significantly reduces the composite outcome of total worsening heart failure events and cardiovascular deaths compared to placebo in patients with preserved or mildly reduced ejection fraction [1].”
Stefanović, M., Trifunović, D., Mladenović, Z., Tadić, S., Apostolovic, S. R., Petrović, O., Vranić, I., Milic, G., Milovančev, A., Krljanać, G., et al. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133651 · Cited by 2
Metadata
- Authors
- Solomon, S. D., McMurray, J. J. V., Vaduganathan, M., Claggett, B., Jhund, P. S., Desai, A. S., Henderson, A. D., Lam, C. S. P., Pitt, B., Senni, M., Shah, S. J., Voors, A. A., Zannad, F., Abidin, I. Z., Alcocer-Gamba, M. A., Atherton, J. J., Bauersachs, J., Chang-Sheng, M., Chiang, C.-E., Chioncel, O., Chopra, V., Comin-Colet, J., Filippatos, G., Fonseca, C., Gajos, G., Goland, S., Goncalvesova, E., Kang, S., Katova, T., Kosiborod, M. N., Latkovskis, G., Lee, A. P.-W., Linssen, G. C. M., Llamas-Esperón, G., Mareev, V., Martinez, F. A., Melenovský, V., Merkely, B., Nodari, S., Petrie, M. C., Saldarriaga, C. I., Saraiva, J. F. K., Sato, N., Schou, M., Sharma, K., Troughton, R., Udell, J. A., Ukkonen, H., Vardeny, O., Verma, S., von Lewinski, D., Voronkov, L., Yilmaz, M. B., Zieroth, S., Lay-Flurrie, J., van Gameren, I., Amarante, F., Kolkhof, P., & Viswanathan, P.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Cardiovascular Division, Brigham and Women’s Hospital, and Harvard Medical School, Boston (S.D.S., M.V., B.C., A.S.D.); British Heart Foundation Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow (J.J.V.M., P.S.J., A.D.H., M.C.P.), and Bayer, Reading (J.L.-F.) — both in the United Kingdom; National Heart Centre Singapore and Duke–National University of Singapore, Singapore (C.S.P.L.); University of Michigan School of Medicine, Ann Arbor (B.P.); University of Milano-Bicocca and Papa Giovanni XXIII Hospital, Bergamo (M. Senni), and the Department of Cardiology, University of Brescia, and ASST “Spedali Civili” Hospital, Brescia (S.N.) — all in Italy; Northwestern University Feinberg School of Medicine, Chicago (S.J.S.); University Medical Center Groningen, Groningen (A.A.V.), the Department of Cardiology, Hospital Group Twente, Almelo (G.C.M.L.), and Bayer, Hoofddorp (I.G.) — all in the Netherlands; Université de Lorraine, INSERM Clinical Inv...
- ORCID
- Solomon, Scott D.
- McMurray, John J.V.
- Vaduganathan, Muthiah
- Claggett, Brian
- Jhund, Pardeep S.
- Desai, Akshay S.
- Henderson, Alasdair D.
- Lam, Carolyn S.P.
- Pitt, Bertram
- Senni, Michele
- Shah, Sanjiv J.
- Voors, Adriaan A.
- Zannad, Faiez
- Abidin, Imran Zainal
- Alcocer-Gamba, Marco Antonio
- Atherton, John J.
- Bauersachs, Johann
- Chiang, Chern-En
- Chioncel, Ovidiu
- Chopra, Vijay
- Filippatos, Gerasimos
- Fonseca, Cândida
- Gajos, Grzegorz
- Goland, Sorel
- Kosiborod, Mikhail N.
- Latkovskis, Gustavs
- Lee, Alex Pui-Wai
- Linssen, Gerard C.M.
- Melenovský, Vojtěch
- Merkely, Béla
- Nodari, Savina
- Petrie, Mark C.
- Saldarriaga, Clara Inés
- Saraiva, Jose Francisco Kerr
- Sato, Naoki
- Schou, Morten
- Troughton, Richard
- Udell, Jacob A.
- Ukkonen, Heikki
- Vardeny, Orly
- Verma, Subodh
- von Lewinski, Dirk
- Voronkov, Leonid
- Zieroth, Shelley
- Kolkhof, Peter
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-10-24
- Volume
- 391
- Issue
- 16
- Pages
- 1475-1485
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4402101139
- Cited by
- 893
- References
- 21
- Citations by year
- 2026: 414 · 2025: 398 · 2024: 81
- FWCI
- 268.66
- Type
- journal article
- Language
- en
- Open access
- green
- hal.univ-lorraine.fr
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Jagiellonian University Repository (Jagiellonian University) (submittedVersion, cc-by-nc-nd)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Bayer
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- finerenone, heart failure with mildly reduced ejection fraction, heart failure with preserved ejection fraction, mineralocorticoid receptor antagonists, non-steroidal mineralocorticoid receptor antagonists, cardiovascular mortality, hyperkalemia, hypokalemia, FINEARTS-HF trial, left ventricular ejection fraction, heart failure hospitalization, drug safety
- MeSH terms
- Aged, Aged, 80 and over, Mineralocorticoid Receptor Antagonists, Double-Blind Method, Female, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Naphthyridines, Stroke Volume, Treatment Outcome, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.